


FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/616,409	ATTY. DOCKET NO.: 10248.70024US00
		FILING DATE: July 9, 2003	CONFIRMATION NO.: 9289
		APPLICANT: Adams et al.	
		GROUP ART UNIT: 1642	EXAMINER: Brandon J. Fetterolf
Sheet	4		



U.S. PATENT DOCUMENTS					
Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,780,454		Adams et al.	07-14-1998
		6,890,898	B2	Bachovchin et al.	05-10-2005
		7,230,074	B2	Bachovchin et al.	06-12-2007
		2001-0020006	A1	Demuth et al.	09-06-2001
		2002-0049164	A1	Demuth et al.	04-25-2002
		2004-0043919	A1	Von Horsten et al.	03-04-2004
		2004-0171555	A1	Demuth et al.	09-02-2004
		2005-0070459	A1	Bachovchin et al.	03-31-2005
		2005-0070482	A1	Bachovchin	03-31-2005

FOREIGN PATENT DOCUMENTS							
Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		DD	294711	A5	Martin-Luther-Universitaet Halle	10-10-1991	Y-Abstract
		DE	19834591	A1	Probiodrug Gesellschaft für Arzneimittelforschung mbH	02-03-2000	Y-Abstract
		EP	0 481 311	A3	Merck Patent Gesellschaft mit Beschränkter Haftung	04-22-1992	Y-Abstract
		EP	0 995 440	A1	Probiodrug Gesellschaft für Arzneimittelforschung mbH	04-26-2000	Y-Abstract
		EP	1 084 705	A2	Probiodrug Gesellschaft für Arzneimittelforschung mbH	03-21-2001	Y-Abstract
		WO	89/12458	A1	Cell Med, Inc.	12-28-1989	
		WO	94/20526	A1	Sandoz Ltd. et al.	09-15-1994	
		WO	94/28915	A1	Institut Pasteur	12-22-1994	Y-Abstract
		WO	95/12618	A1	Eurogenetics N.V.	05-11-1995	
		WO	95/29233	A1	Ludwig Institute for Cancer Research	11-02-1995	
		WO	95/29691	A1	Georgia Tech Research Corporation	11-09-1995	
		WO	97/40832	A1	Hans-Knöll-Institut für Naturstoff-	11-06-1997	Y-Abstract

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00	
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289	
				APPLICANT: Adams et al.			
				GROUP ART UNIT: 1642		EXAMINER: Brandon J. Fetterolf	
Sheet	2	of	4				

		WO	97/45117	A1	Prototek, Inc.	12-04-1997	
		WO	99/28474	A2	The Government of the United States of America	06-10-1999	
		WO	99/38501	A2	Trustees of Tufts University	08-05-1999	
		WO	99/46272	A1	Fondatech Benelux N.V.	09-16-1999	
		WO	99/61431	A1	Probiobdrug Gesellschaft für	12-02-1999	Y-Abstract
		WO	99/67278	A1	Pro-Biodrug Gesellschaft für	12-29-1999	Y-Abstract
		WO	2003/045228	A2	Trustees of Tufts College	06-05-2003	
		WO	2003/045977	A2	Trustees of Tufts College	06-05-2003	
		WO	2005/082348	A2	Trustees of Tufts College	09-09-2005	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	Press Release, Point Therapeutics, Talabostat Clinical Program Put on Clinical Hold by FDA: Decision Based on Results of the Interim Analyses of the Talabostat Phase 3 Program in Lung Cancer. May 21, 2007. 1 page.	
	Press Release, Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP ₄ Inhibitor, ARI-2243, at the ADA. June 25, 2007. 2 pages.	
	ANSORGE et al., Dipeptidyl peptidase IV (DP IV), a functional marker of the T lymphocyte system. Acta Histochem. 1987;82(1):41-6. Abstract Only.	
	AOYAGI et al., Multiple enzymes related to differentiation of lymphocyte subpopulations in man. Biochem Int. 1989 Feb;18(2):383-9.	
	BACHOVCHIN et al., Inhibition of IgA1 proteinases from Neisseria gonorrhoeae and Hemophilus influenzae by peptide prolyl boronic acids. J Biol Chem. 1990 Mar 5;265(7):3738-43.	
	BODUSZEK et al., Dipeptide phosphonates as inhibitors of dipeptidyl peptidase IV. J Med Chem. 1994 Nov 11;37(23):3969-76.	
	CHEN et al., Dipeptidyl peptidase IV gene family. The DPIV family. Adv Exp Med Biol. 2003;524:79-86.	
	CUNNINGHAM et al., Phase 2 Study of Talabostat and Cisplatin in Stage IV Melanoma. American Society of Clinical Oncology (ASCO) Annual Meeting. Orlando, Florida. May 14, 2005. Abstract 7563.	
	DANG et al., 1F7 (CD26): a marker of thymic maturation involved in the differential regulation of the CD3 and CD2 pathways of human thymocyte activation. J Immunol. 1991 Nov 1;147(9):2825-32. Abstract Only.	
	DANG et al., Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol. 1990 Jun 1;144(11):4092-100. Abstract Only.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409		ATTY. DOCKET NO.: 10248.70024US00	
				FILING DATE: July 9, 2003		CONFIRMATION NO.: 9289	
				APPLICANT: Adams et al.			
				GROUP ART UNIT: 1642		EXAMINER: Brandon J. Fetterolf	
Sheet	3	of	4				

	DEMUTH et al., Design of (omega-N-(O-acyl)hydroxy amid) aminodicarboxylic acid pyrrolidides as potent inhibitors of proline-specific peptidases. FEBS Lett. 1993 Mar 29;320(1):23-7.	
	DONG et al., Role of CD26 for CD4 memory T cell function and activation. Hum Cell. 1996 Sep;9(3):153-62. Abstract Only.	
	FLEISCHER et al., CD26: a surface protease involved in T-cell activation. Immunol Today. 1994 Apr;15(4):180-4. Abstract Only.	
	GOPAL et al., High does I-131-anti cd-20 antibody therapy (tositumomab), etoposide, cyclophosphamide and autologous stem cell transplantation for patients with relapsed or refractory mantle cell lymphoma. Proc Am Soc Clin Oncol. 2001; 20. Abstract 1118.	
	HAFLER et al., Mechanisms of immune memory. T cell activation and CD3 phosphorylation correlates with Ta1 (CDw26) expression. J Immunol. 1989 Apr 15;142(8):2590-6. Abstract Only.	
	HEYMANN et al., Liver dipeptidyl aminopeptidase IV hydrolyzes substance P. FEBS Lett. 1978 Jul 15;91(2):360-4.	
	HUGHES et al., NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry. 1999 Sep 7;38(36):11597-603.	
	KETTNER et al., Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. J Biol Chem. 1984 Dec 25;259(24):15106-14.	
	REDMAN et al., Phase 2 Trial of Talabostat in Stage IV Melanoma. American Society of Clinical Oncology (ASCO) Annual Meeting, Orlando, Florida. May 14, 2005. Abstract 7570.	
	REINHOLD et al., CD26 mediates the action of HIV-1 Tat protein on DNA synthesis and cytokine production in U937 cells. Immunobiology. 1996 Jan;195(1):119-28.	
	REINHOLD et al., The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity. Biol Chem. 2002 Jul-Aug;383(7-8):1133-8.	
	SHIODA et al., Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6331-6.	
	SUN et al., Expression, purification, and kinetic characterization of full-length human fibroblast activation protein. Protein Expr Purif. 2002 Mar;24(2):274-81. Abstract Only.	
	TANAKA et al., The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4586-90. Abstract Only.	
	TORIMOTO et al., Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes. J Immunol. 1991 Oct 15;147(8):2514-7. Abstract Only.	
	VIVIER et al., Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J Immunol. 1991 Jul 15;147(2):447-54. Abstract Only.	
	YAMADA et al., A potent dipeptide inhibitor of dipeptidyl peptidase IV. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1537-40.	
	ZHAO et al., Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoro-propylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg Med Chem. 2003 Jan	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,409	ATTY. DOCKET NO.: I0248.70024US00
				FILING DATE: July 9, 2003	CONFIRMATION NO.: 9289
				APPLICANT: Adams et al.	
				GROUP ART UNIT: 1642	EXAMINER: Brandon J. Fetterolf
Sheet	4	of	4		

	17;11(2):207-15.	
--	------------------	--

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.